SCHEMBL8285387

SCHEMBL8285387

CC1CN(C(=O)OC(C)(C)C)CCN1C(=S)Nc1ccc(Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
POLB P06746 1/20 0.46
LMNA P02545 3/20 0.46
GAA P10253 2/20 0.46
HPGD P15428 1/20 0.46
STS P08842 2/20 0.46
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN6 P29350 1/20 0.46
SETD7 Q8WTS6 1/20 0.46
NR3C1 P04150 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
USP30 Q70CQ3 1/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8285767 0.91 MAPT (0.57) MAPTL3MBTL1MEN1KMT2APOLB
SCHEMBL19284201 0.89 MEN1 (0.50) MAPTL3MBTL1MEN1KMT2ASTS
SCHEMBL19284239 0.85 MAPT (0.53) MAPTL3MBTL1MEN1KMT2APOLB
SCHEMBL316048 0.85 MAPT (0.61) MAPTL3MBTL1MEN1KMT2APOLB
SCHEMBL314325 0.81 MAPT (0.61) MAPTL3MBTL1MEN1KMT2APOLB
SCHEMBL10189872 0.81 MEN1 (0.64) MAPTMEN1KMT2ALMNAGAA
SCHEMBL26546984 0.78 HTT (0.49) POLBHPGDNPSR1NPC1HTT
SCHEMBL26546975 0.78 HTT (0.49) POLBHPGDNPSR1NPC1HTT
SCHEMBL27748371 0.78 HPGD (0.55) MEN1KMT2AHPGDSTSSETD7
SCHEMBL3599783 0.77 MEN1 (0.47) MAPTL3MBTL1MEN1KMT2ASTS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093400-B2 Compounds useful in therapy PFIZER INC. (US) 2012-01-10 US disclosed
US-8093400-B2 Compounds useful in therapy PFIZER INC. (US) 2012-01-10 US disclosed
US-20100317652-A1 Compounds Useful In Therapy PFIZER INC 2010-12-16 US disclosed
US-20100317652-A1 Compounds Useful In Therapy PFIZER INC 2010-12-16 US disclosed
US-7745630-B2 Triazolyl piperidine arginine vasopressin receptor modulators BRYANS JUSTIN STEPHEN 2010-06-29 US disclosed
US-7745630-B2 Triazolyl piperidine arginine vasopressin receptor modulators BRYANS JUSTIN STEPHEN 2010-06-29 US disclosed
WO-2005063754-A1 TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS PFIZER LIMITED (GB) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317652-A1 Compounds Useful In Therapy AVPR1A, AVPR1B, AVPR2 MAPT 4518/4885L3MBTL1 4863/4885MEN1 1081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.